Martin Auster
Stock Analyst at UBS
(2.18)
# 2,575
Out of 4,789 analysts
47
Total ratings
51.61%
Success rate
4.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $70.69 | +69.76% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $36.21 | +189.98% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $2.88 | +802.78% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $3.70 | +3,143.24% | 4 | Mar 16, 2021 | |
| GLTO Galecto | Maintains: Outperform | $725 → $300 | $3.10 | +9,577.42% | 2 | Mar 16, 2021 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $49 → $58 | $6.65 | +772.18% | 3 | Mar 10, 2021 | |
| UTHR United Therapeutics | Maintains: Outperform | $169 → $196 | $308.27 | -36.42% | 4 | Feb 22, 2021 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $62 → $98 | $0.62 | +15,630.34% | 2 | Feb 11, 2021 | |
| INSM Insmed | Maintains: Outperform | $50 → $60 | $76.29 | -21.35% | 2 | Jan 19, 2021 | |
| SRRK Scholar Rock Holding | Initiates: Outperform | $65 | $32.15 | +102.18% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $63.82 | +14.38% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $2.77 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $10.60 | +635.85% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.44 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $6.60 | +551.52% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $29.52 | +15.18% | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $7.11 | +195.36% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $18.59 | -13.93% | 1 | May 7, 2020 |
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $70.69
Upside: +69.76%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $36.21
Upside: +189.98%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $2.88
Upside: +802.78%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $3.70
Upside: +3,143.24%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $3.10
Upside: +9,577.42%
Stoke Therapeutics
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $6.65
Upside: +772.18%
United Therapeutics
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $308.27
Upside: -36.42%
ALX Oncology Holdings
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $0.62
Upside: +15,630.34%
Insmed
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $76.29
Upside: -21.35%
Scholar Rock Holding
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $32.15
Upside: +102.18%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $63.82
Upside: +14.38%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $2.77
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $10.60
Upside: +635.85%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $1.44
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $6.60
Upside: +551.52%
Jul 7, 2020
Initiates: Outperform
Price Target: $34
Current: $29.52
Upside: +15.18%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $7.11
Upside: +195.36%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $18.59
Upside: -13.93%